Added to YB: 2026-01-06
Pitch date: 2026-01-03
IVVD [bullish]
Invivyd, Inc.
-55.98%
current return
Author Info
JNap is Head of Research for Remsen Investors LP, a long/short biopharma fund and owner of Bio5C, an independent biopharma research service. Sign up for the newsletter.
Company Info
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
Market Cap
$415.7M
Pitch Price
$2.51
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.59
P/E
-4.82
EV/Sales
3.58
Sector
Biotechnology
Category
growth
Six Lottos For 2026 - Invivyd, Inc.
IVVD (lotto play): COVID remains high-risk w/ <50% vaccine efficacy, 25% uptake. Only approved non-mRNA alternative Pemgarda limited by IV infusion. VYD-2311 3rd-gen candidate enables IM injection, 6-mo dosing. Phase 3 trials Declaration & Liberty enrolling, data Q2 2026. $750M mcap vs multi-billion booster market potential - 10% of 60M Americans = $3B sales. Cidara 2.0 opportunity.
Read full article (2 min)